November 20, 2014
Coming on the heels of a mistrial bid, Ranbaxy Inc. and AstraZeneca PLC moved for judgment Thursday in a pay-for-delay case unfolding in Massachusetts federal court over the heartburn drug Nexium, arguing no reasonable jury could find the companies schemed to delay a generic version of the drug.
November 19, 2014
Ranbaxy Laboratories Ltd. moved for a mistrial Wednesday in a pay-for-delay case in Massachusetts federal court over the heartburn treatment Nexium, arguing the court's shifting stance on the nature of the generic producer's antitrust liability in the case has prejudiced the company.
November 10, 2014
AstraZeneca PLC and two generic-drug makers asked a Massachusetts federal court on Monday for judgment on all claims in a pay-for-delay case over the heartburn treatment Nexium, arguing that the plaintiffs hadn't shown that a $9 million deal in a separate patent suit constituted a large, unjustified payment.
November 05, 2014
Nexium buyers in a pay-for-delay case against AstraZeneca PLC and two generic-drug makers on Wednesday asked a Massachusetts federal judge to order AstraZeneca to hand over key litigation and settlement documents for trial, saying the company is using privilege as a "sword and a shield."
October 22, 2014
A Walgreen Co. executive testified Wednesday at a pay-for-delay trial over AstraZeneca PLC's Nexium that the heartburn treatment did face competition for prescriptions from several other similar drugs, but emphasized that cheaper generic versions were only available for a few lower dosages.
October 21, 2014
Nexium buyers pursuing a pay-for-delay case against AstraZeneca PLC and two generic-drug makers told a Boston federal jury on Tuesday that the pharmaceutical companies were trying to game the patent system to overcharge consumers by billions of dollars for the heartburn treatment.
October 21, 2014
As the first pay-for-delay jury trial kicked off Tuesday, a Boston federal judge told jurors that though patent settlements are usually good, a large and unexplained payment in the case over Nexium could spell trouble under antitrust law.
October 20, 2014
Dr. Reddy's Laboratories Ltd. agreed Sunday to help drug buyers make their pay-for-delay case against AstraZeneca PLC and two generic-drug makers as part of a settlement inked on the eve of trial in the antitrust class action.
October 09, 2014
A Covington & Burling LLP partner does not have to offer live testimony in the upcoming pay-for-delay trial in multidistrict litigation against AstraZeneca PLC over the heartburn drug Nexium, a Massachusetts federal judge ruled Thursday, ending a contentious dispute over whether a prerecorded deposition should suffice.
October 06, 2014
A Covington & Burling LLP partner said Monday that the plaintiffs' subpoena, in an upcoming pay-for-delay trial in multidistrict litigation against AstraZeneca PLC over the heartburn drug Nexium, forcing him to offer live testimony via video feed amounts to a "reckless attack" on his reputation.